The Power of Community will Make Advancements in Predictive Toxicology - An Interview with Janssen’s David Gallacher
Pharma IQ: What are the major challenges we face in predictive toxicology? David Gallacher: One of the major challenges that we have is the lack of good predictive in silico methods at this stage, especially in relation to cardio-vascular safety research, essentially one of the largest causes of drug withdrawal within the pharmaceutical industry. Another challenge is in relation to liver toxicity in that there are a number of adverse effects and idiosyncratic effects of certain compounds that ha...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.